Cargando…

Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy

BACKGROUND/AIMS: For metastatic renal cell carcinoma (RCC), various prognostic scoring systems have been developed. However, owing to the low prevalence of nonclear cell RCC, the three most commonly used tools were mainly developed based on patients with clear cell histology. Accordingly, this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, In Hee, Kang, Byung Woog, Kim, Jong Gwang, Bae, Woo Kyun, Ki, Myung Seo, Park, Inkeun, Jo, Jae-Cheol, Kim, Jin Young, Koh, Sung Ae, Lee, Kyung Hee, Cho, Yoon Young, Ryoo, Hun Mo, Kwak, Sang Gyu, Lee, Jung Lim, Lee, Sun Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960037/
https://www.ncbi.nlm.nih.gov/pubmed/30301310
http://dx.doi.org/10.3904/kjim.2018.064
_version_ 1783487702644031488
author Lee, In Hee
Kang, Byung Woog
Kim, Jong Gwang
Bae, Woo Kyun
Ki, Myung Seo
Park, Inkeun
Jo, Jae-Cheol
Kim, Jin Young
Koh, Sung Ae
Lee, Kyung Hee
Cho, Yoon Young
Ryoo, Hun Mo
Kwak, Sang Gyu
Lee, Jung Lim
Lee, Sun Ah
author_facet Lee, In Hee
Kang, Byung Woog
Kim, Jong Gwang
Bae, Woo Kyun
Ki, Myung Seo
Park, Inkeun
Jo, Jae-Cheol
Kim, Jin Young
Koh, Sung Ae
Lee, Kyung Hee
Cho, Yoon Young
Ryoo, Hun Mo
Kwak, Sang Gyu
Lee, Jung Lim
Lee, Sun Ah
author_sort Lee, In Hee
collection PubMed
description BACKGROUND/AIMS: For metastatic renal cell carcinoma (RCC), various prognostic scoring systems have been developed. However, owing to the low prevalence of nonclear cell RCC, the three most commonly used tools were mainly developed based on patients with clear cell histology. Accordingly, this study applied three prognostic models to Korean non-clear cell RCC patients treated with first-line temsirolimus. METHODS: This study analyzed data for 74 patients with non-clear cell RCC who were treated with temsirolimus as the first-line therapy at eight medical centers between 2011 and 2016. The receiver-operating characteristic (ROC) curves for the different prognostic models were analyzed. RESULTS: Twenty-seven (36.5%), 24 (32.4%), and 44 patients (59.5%) were assigned to the poor prognosis groups of the Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic RCC Database Consortium (IMDC), and Advanced Renal Cell Carcinoma (ARCC) risk stratification models, respectively. All three prognostic models reliably discriminated the risk groups to predict progression-free survival and overall survival (p < 0.001). The area under the ROC curve (AUC) for progression and survival was highest for the ARCC model (0.777; 0.734), followed by the IMDC (0.756; 0.724) and the MSKCC (0.742; 0.712) models. Furthermore, the sensitivity and specificity for predicting progression were highest with the ARCC model (sensitivity 63.6%, specificity 85.7%), followed by the MSKCC (sensitivity 58.2%, specificity 86.5%) and the IMDC models (sensitivity 56.4%, specificity 85.7%). CONCLUSIONS: All three prognostic models accurately predicted the survival of the non-clear cell RCC patients treated with temsirolimus as the first-line therapy. Furthermore, the ARCC risk model performed better than the other risk models in predicting survival.
format Online
Article
Text
id pubmed-6960037
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-69600372020-01-22 Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy Lee, In Hee Kang, Byung Woog Kim, Jong Gwang Bae, Woo Kyun Ki, Myung Seo Park, Inkeun Jo, Jae-Cheol Kim, Jin Young Koh, Sung Ae Lee, Kyung Hee Cho, Yoon Young Ryoo, Hun Mo Kwak, Sang Gyu Lee, Jung Lim Lee, Sun Ah Korean J Intern Med Original Article BACKGROUND/AIMS: For metastatic renal cell carcinoma (RCC), various prognostic scoring systems have been developed. However, owing to the low prevalence of nonclear cell RCC, the three most commonly used tools were mainly developed based on patients with clear cell histology. Accordingly, this study applied three prognostic models to Korean non-clear cell RCC patients treated with first-line temsirolimus. METHODS: This study analyzed data for 74 patients with non-clear cell RCC who were treated with temsirolimus as the first-line therapy at eight medical centers between 2011 and 2016. The receiver-operating characteristic (ROC) curves for the different prognostic models were analyzed. RESULTS: Twenty-seven (36.5%), 24 (32.4%), and 44 patients (59.5%) were assigned to the poor prognosis groups of the Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic RCC Database Consortium (IMDC), and Advanced Renal Cell Carcinoma (ARCC) risk stratification models, respectively. All three prognostic models reliably discriminated the risk groups to predict progression-free survival and overall survival (p < 0.001). The area under the ROC curve (AUC) for progression and survival was highest for the ARCC model (0.777; 0.734), followed by the IMDC (0.756; 0.724) and the MSKCC (0.742; 0.712) models. Furthermore, the sensitivity and specificity for predicting progression were highest with the ARCC model (sensitivity 63.6%, specificity 85.7%), followed by the MSKCC (sensitivity 58.2%, specificity 86.5%) and the IMDC models (sensitivity 56.4%, specificity 85.7%). CONCLUSIONS: All three prognostic models accurately predicted the survival of the non-clear cell RCC patients treated with temsirolimus as the first-line therapy. Furthermore, the ARCC risk model performed better than the other risk models in predicting survival. The Korean Association of Internal Medicine 2020-01 2018-10-12 /pmc/articles/PMC6960037/ /pubmed/30301310 http://dx.doi.org/10.3904/kjim.2018.064 Text en Copyright © 2020 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, In Hee
Kang, Byung Woog
Kim, Jong Gwang
Bae, Woo Kyun
Ki, Myung Seo
Park, Inkeun
Jo, Jae-Cheol
Kim, Jin Young
Koh, Sung Ae
Lee, Kyung Hee
Cho, Yoon Young
Ryoo, Hun Mo
Kwak, Sang Gyu
Lee, Jung Lim
Lee, Sun Ah
Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
title Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
title_full Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
title_fullStr Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
title_full_unstemmed Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
title_short Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
title_sort comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960037/
https://www.ncbi.nlm.nih.gov/pubmed/30301310
http://dx.doi.org/10.3904/kjim.2018.064
work_keys_str_mv AT leeinhee comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT kangbyungwoog comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT kimjonggwang comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT baewookyun comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT kimyungseo comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT parkinkeun comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT jojaecheol comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT kimjinyoung comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT kohsungae comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT leekyunghee comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT choyoonyoung comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT ryoohunmo comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT kwaksanggyu comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT leejunglim comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy
AT leesunah comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy